

<u>Freedom of Information Act 2000 - Request Reference Fol/22/179</u> Dermatology Treatments

I am analysing the treatment of dermatological conditions in the UK. Could you please answer the following questions?

Q1. How many patients were treated in last 4 months by the Dermatology department with each of the following:

- Abrocitinib 0
- Acitretin*
- Alitretinoin*
- Azathioprine*
- Baricitinib: 3
- Ciclosporin*
- Dupilumab 63
- Methotrexate*
- Mycophenolate mofetil*
- Pimecrolimus*
- Tacrolimus ointment 1
- Tralokinumab 0
- Upadacitinib 0

*Please note: Cardiff and Vale University Health Board (the UHB) does not hold this information. Under Section 16 of the FOIA, which provides us with the duty to advise and assist, the UHB can inform you that prescriptions for the drugs above, will routinely be generated in hospital but dispensed in the community – the COPPS prescribing system. The UHB therefore wouldn't have the information on our system that identifies how many patients have received the drug on our behalf.

Q2. Of the patients treated in the last 4 months with any of the products listed in Q1, how many patients were paediatric (age 17 or under)?

6

Q3. How many patients were treated in the last 4 months with phototherapy (UVB or PUVA) for atopic Dermatitis ONLY?

We have treated 106 UVB patients We have treated 24 UVA patients

Figures above from January 2022 to April 2022



